This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Sunitinib

From Proteopedia

Revision as of 12:14, 9 December 2010 by David Canner (Talk | contribs)
Jump to: navigation, search

Sunitinib, also known as Sutent, (3g0e)

Drag the structure with the mouse to rotate

Better Known as: Sutent

  • Marketed By: Pfizer
  • Major Indication: Renal Cell Carcinoma & Stomach Cancer
  • Drug Class: Receptor Tyrosine Kinase (Including VEGFR & PDGFR) Inhibitor
  • Date of FDA Approval (Patent Expiration): 2006 (2020)
  • 2009 Sales: $964 Million [1]
  • Importance:
  • See Pharmaceutical Drugs for more information about other drugs and disorders.

Mechanism of Action

Pharmacokinetics

VEGFR Inhibitor Pharmacokinetics [2][3][4][5][6]
Parameter Sunitinib (Sutent) Sorafenib (Nexavar)
Tmax (hr) 8 8.3
Cmax (ng/ml) 24.6 460
Bioavailability (%) Variable 29-49
Protein Binding (%) 95 99
T1/2 (hr) 83 29
AUC (ng/ml/hr) 1921 11040
Dosage (mg) 50 50
Metabolism Hepatic (CYP3A4) Hepatic (CYP3A4)

References

  1. ↑ http://www.inpharm.com/news/101125/renal-cell-carcinoma-market-votrient-sutent
  2. ↑ D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.
  3. ↑ R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)
  4. ↑ Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006 May;57(5):685-92. Epub 2005 Aug 25. PMID:16133532 doi:10.1007/s00280-005-0068-6
  5. ↑ Brendel E, Ludwig M, Lathia C, Robert C, Ropert S, Soria JC, Armand JP. Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010 Sep 7. PMID:20821331 doi:10.1007/s00280-010-1423-9
  6. ↑ Boven E, Massard C, Armand JP, Tillier C, Hartog V, Brega NM, Countouriotis AM, Ruiz-Garcia A, Soria JC. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. Br J Cancer. 2010 Sep 28;103(7):993-1000. Epub 2010 Aug 17. PMID:20717111 doi:10.1038/sj.bjc.6605852


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky, Joel L. Sussman

Retrieved from "http://52.214.119.220/wiki/index.php/Sunitinib"
Personal tools